SCHEMBL251940

SCHEMBL251940

CCCN1CCCN2CCCN=C12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYP1A2 P05177 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 3/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 3/20 0.34
POLB P06746 1/20 0.34
USP2 O75604 1/20 0.33
INMT O95050 1/20 0.33
KDM2B Q8NHM5 1/20 0.32
PDE4A P27815 2/20 0.31
PDE4B Q07343 2/20 0.31
PDE4C Q08493 2/20 0.31
PDE4D Q08499 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9984629 0.95 CYP2D6 (0.41) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL2740903 0.93 CYP2D6 (0.42) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL252415 0.89 CYP2D6 (0.44) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL8368647 0.88 ALDH1A1 (0.45) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL253401 0.86 ALDH1A1 (0.47) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL17217520 0.86 ALDH1A1 (0.47) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL9131907 0.86 ALDH1A1 (0.47) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL250783 0.86 ALDH1A1 (0.47) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL23075888 0.85 USP2 (0.35) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1
SCHEMBL22106057 0.85 USP2 (0.35) CYP2D6CYP3A4CYP2C19CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10640641-B2 Curable coating compositions of silane functional polymers KING INDUSTRIES (US) 2020-05-05 US claimed
US-20200062953-A1 CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS KING INDUSTRIES 2020-02-27 US claimed
US-20190248721-A1 PROCESSES FOR PREPARING CALIXARENES SI GROUP, INC. 2019-08-15 US claimed
US-10336863-B2 Curable composition having a special catalyst/softner system HENKEL AG & CO. KGAA (DE) 2019-07-02 US claimed
US-20180237635-A1 CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS KING INDUSTRIES 2018-08-23 US claimed
US-9976028-B2 Curable coating compositions of silane functional polymers KING INDUSTRIES (US) 2018-05-22 US claimed
US-9944593-B2 Process for the synthesis of fluoralkyl sulfonate salts SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) 2018-04-17 US claimed
EP-1930376-B2 CURABLE COMPOSITION KANEKA CORP (JP) 2016-09-07 EP claimed
WO-2016137881-A1 CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS KING INDUSTRIES (US) 2016-09-01 WO claimed
US-20160244606-A1 CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS KING INDUSTRIES 2016-08-25 US claimed
WO-2012036392-A3 HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING THE SAME 주식회사 아이지세라피 (KR) 2012-05-10 WO claimed
EP-1930376-B1 CURABLE COMPOSITION KANEKA CORP (JP) 2011-12-07 EP claimed
US-8013080-B2 Curable composition KANEKA CORPORATION (JP) 2011-09-06 US claimed
EP-0626410-B1 Method for making polycarbonates GEN ELECTRIC (US) 1999-01-07 EP claimed
EP-0626410-A2 Method for making polycarbonates GENERAL ELECTRIC COMPANY (US) 1994-11-30 EP claimed
US-5319066-A Method for making polycarbonates GENERAL ELECTRIC COMPANY (US) 1994-06-07 US claimed
EP-4692247-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-02-11 EP disclosed
EP-4692148-A1 CURABLE COMPOSITION AND CURED PRODUCT OF SAME DIC Corporation (JP) 2026-02-11 EP disclosed
EP-0626410-A2 Method for making polycarbonates GENERAL ELECTRIC COMPANY (US) 1994-11-30 EP disclosed
US-5319066-A Method for making polycarbonates GENERAL ELECTRIC COMPANY (US) 1994-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248721-A1 PROCESSES FOR PREPARING CALIXARENES CALU, CALD1, CALR CYP2D6 1274/4885CYP3A4 262/4885CYP2C19 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.